ZTS Stock Recent News

In the latest trading session, Zoetis (ZTS) closed at $145.54, marking a -0.66% move from the previous day.

Zoetis Inc. has seen a significant decline in its stock price, dropping more than 24% since January. The decline is partly due to market weakness and the ongoing growth to value rotation, as well as headlines about the potential adverse effects of one of its key drugs. Despite the setbacks, Zoetis' core business remains strong, with robust top-line and bottom-line growth expectations, diversified growth opportunities, and a stable dividend.

Zoetis Inc (NYSE:ZTS, ETR:ZOE) shares took a hit Friday after a Wall Street Journal report that suggested the company's arthritis shots may have sickened dogs and cats. The arthritis shots, Librela and Solensia, target osteoarthritis by focusing on nerve growth factor protein.

An article in The Wall Street Journal highlights the scrutiny over the company's arthritis treatments for pets.

Zoetis Inc.'s stock ZTS, -7.77% tumbled 7% Friday to lead S&P 500 decliners, after a Wall Street Journal report that the company's arthritis shots Librela and Solensia may have sickened pet cats and dogs. The two shots won Food and Drug Administration approval in 2022 and 2023 as the first antibody drugs for pets.

The latest trading day saw Zoetis (ZTS) settling at $165.69, representing a -0.1% change from its previous close.

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 2, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2024 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentation.

Zoetis Inc. has shown unique compounding results since spinning off from Pfizer, with double-digit EPS and dividend growth CAGRs since inception. The loneliness epidemic is driving demand for companion animals, and Zoetis is well positioned to benefit from the rise in pet ownership and pet-related spending. Zoetis has a strong position in the animal health market, with increased pricing power and limited competition, making it a best-in-class asset in the industry.

The SPDR S&P 500 ETF Trust had a 5.22% return in February, outperforming Vanguard's Dividend Appreciation Index Fund ETF Shares.

Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness